A detailed history of Rubric Capital Management LP transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Rubric Capital Management LP holds 10,966,672 shares of ARQT stock, worth $155 Million. This represents 2.84% of its overall portfolio holdings.

Number of Shares
10,966,672
Previous 9,816,672 11.71%
Holding current value
$155 Million
Previous $91.3 Million 11.71%
% of portfolio
2.84%
Previous 2.7%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$8.32 - $11.0 $9.57 Million - $12.7 Million
1,150,000 Added 11.71%
10,966,672 $102 Million
Q2 2024

Aug 13, 2024

BUY
$7.24 - $12.53 $16.7 Million - $28.9 Million
2,306,672 Added 30.71%
9,816,672 $91.3 Million
Q1 2024

May 10, 2024

BUY
$3.25 - $11.77 $2.81 Million - $10.2 Million
865,470 Added 13.03%
7,510,000 $74.4 Million
Q4 2023

Feb 13, 2024

BUY
$1.84 - $4.82 $2.96 Million - $7.76 Million
1,610,000 Added 31.98%
6,644,530 $21.5 Million
Q3 2023

Nov 14, 2023

BUY
$5.31 - $10.98 $796,499 - $1.65 Million
150,000 Added 3.07%
5,034,530 $26.7 Million
Q2 2023

Aug 11, 2023

BUY
$7.51 - $15.0 $10.4 Million - $20.8 Million
1,384,530 Added 39.56%
4,884,530 $46.5 Million
Q1 2023

May 12, 2023

BUY
$10.23 - $17.14 $7.75 Million - $13 Million
757,481 Added 27.62%
3,500,000 $38.5 Million
Q4 2022

Feb 10, 2023

BUY
$13.96 - $20.4 $31.7 Million - $46.3 Million
2,270,472 Added 480.98%
2,742,519 $40.6 Million
Q3 2022

Nov 14, 2022

BUY
$17.85 - $26.95 $4.39 Million - $6.62 Million
245,701 Added 108.55%
472,047 $9.02 Million
Q2 2022

Aug 15, 2022

BUY
$16.33 - $22.2 $3.7 Million - $5.02 Million
226,346 New
226,346 $4.82 Million

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $849M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Rubric Capital Management LP Portfolio

Follow Rubric Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rubric Capital Management LP with notifications on news.